Given whole suppression of effector T-cell response instead of targeting one inflammatory mediators, PD-L1-pHLIP theoretically might be more effective to treat autoimmune diseases than targeting one cytokine, which need validation in vivo in the future. Here, CD274 is linked to autoimmune disease.